Venlafaxine
- Generic Name
- Venlafaxine
- Brand Names
- Effexor
- Drug Type
- Small Molecule
- Chemical Formula
- C17H27NO2
- CAS Number
- 93413-69-5
- Unique Ingredient Identifier
- GRZ5RCB1QG
- Background
Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, desvenlafaxine, works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorder (MDD), generalized anxiety disorder (GAD...
- Indication
Venlafaxine is indicated for the management of major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder (SAD), and panic disorder.
- Associated Conditions
- Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Migraine, Neuropathic Pain, Panic Disorder, Social Anxiety Disorder (SAD), Vasomotor Symptoms Associated With Menopause
- Associated Therapies
- -
Combination Treatment Study for Memory Impairment and Depression
- Conditions
- Interventions
- First Posted Date
- 2012-08-06
- Last Posted Date
- 2017-10-17
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 86
- Registration Number
- NCT01658228
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
🇺🇸Duke University, Durham, North Carolina, United States
Venlafaxine in Preventing Chronic Oxaliplatin-Induced Neuropathy In Patients Receiving Combination Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2012-06-04
- Last Posted Date
- 2019-09-26
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 50
- Registration Number
- NCT01611155
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Venlafaxine for Depression in Alzheimer's Disease (DIADs-3)
- Conditions
- Interventions
- First Posted Date
- 2012-06-01
- Last Posted Date
- 2018-01-31
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 5
- Registration Number
- NCT01609348
- Locations
- 🇺🇸
Johns Hopkins at Bayview, Baltimore, Maryland, United States
🇺🇸Reading Hospital, West Reading, Pennsylvania, United States
The Treatment of Traumatised Refugees With Sertraline Versus Venlafaxine in Combination With Psychotherapy
- Conditions
- Interventions
- First Posted Date
- 2012-04-03
- Last Posted Date
- 2015-03-04
- Lead Sponsor
- Charlotte Sonne
- Target Recruit Count
- 207
- Registration Number
- NCT01569685
- Locations
- 🇩🇰
Competence Center for Transcultural Psychiatry, Gentofte, Denmark
Estimate the Efficiency of the Association of an Injection of Ketamine and the Venlafaxine in the Severe Major Depressive Disorder for Six Weeks
- Conditions
- Interventions
- First Posted Date
- 2012-03-19
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- University Hospital, Grenoble
- Target Recruit Count
- 25
- Registration Number
- NCT01557712
- Locations
- 🇫🇷
Centre hospitalier universitaire, Grenoble, France
Quality of Life Study Using Gabapentin Versus Venlafaxine in Treating Hot Flashes in Patients With Prostate Cancer
- First Posted Date
- 2012-02-15
- Last Posted Date
- 2019-11-21
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 5
- Registration Number
- NCT01533753
- Locations
- 🇺🇸
University of Wisconsin Hospital and Clinics (Carbone Cancer Center), Madison, Wisconsin, United States
Bioavailability Study of Venlafaxine MR Capsules 150 mg Under Fed Conditions
- First Posted Date
- 2012-01-19
- Last Posted Date
- 2012-01-19
- Lead Sponsor
- Dr. Reddy's Laboratories Limited
- Target Recruit Count
- 33
- Registration Number
- NCT01512459
- Locations
- 🇮🇳
Bioserve Clinical Research (P) Ltd, Balanagar, Hyderabad, India
Effect of Duloxetine and Venlafaxine on the Pharmacokinetics and Pharmacodynamics of Oral Tramadol: A Three-phase Randomized Balanced Cross-over Study in Healthy Volunteers
- First Posted Date
- 2011-09-29
- Last Posted Date
- 2012-05-22
- Lead Sponsor
- Turku University Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT01443520
- Locations
- 🇫🇮
Department of Anaesthesiology, Intensive Care, Emergency Care and Pain Medicine, Turku University and Turku University Hospital, Turku, Finland
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
- Conditions
- Interventions
- First Posted Date
- 2011-09-20
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 54
- Registration Number
- NCT01436643
- Locations
- 🇩🇪
Novartis Investigative Site, Zwickau, Germany
Electroencephalography (EEG) Signal Processing
- First Posted Date
- 2011-06-08
- Last Posted Date
- 2011-11-30
- Lead Sponsor
- St. Joseph's Healthcare Hamilton
- Target Recruit Count
- 150
- Registration Number
- NCT01369290
- Locations
- 🇨🇦
St. Joseph's Healthcare, Centre for Mountain Health Services, Hamilton, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.